Based on these total effects, we hypothesize that SARS-CoV-2 infection generates a microenvironment conducive to effective AID expression, leading to an immune system response solid enough to maintain an contaminated person asymptomatic while also creating long-term immunity

Based on these total effects, we hypothesize that SARS-CoV-2 infection generates a microenvironment conducive to effective AID expression, leading to an immune system response solid… Read More »Based on these total effects, we hypothesize that SARS-CoV-2 infection generates a microenvironment conducive to effective AID expression, leading to an immune system response solid enough to maintain an contaminated person asymptomatic while also creating long-term immunity

Differential modulation of B7-1 and B7-2 isoform expression on human monocytes by cytokines which influence the development of T helper cell phenotype

Differential modulation of B7-1 and B7-2 isoform expression on human monocytes by cytokines which influence the development of T helper cell phenotype. NVP-TAE 226 after… Read More »Differential modulation of B7-1 and B7-2 isoform expression on human monocytes by cytokines which influence the development of T helper cell phenotype

A phase 1 clinical trial of DSP107 alone and in combination with atezolizumab for patients with advanced solid tumors is in the recruitment phase (“type”:”clinical-trial”,”attrs”:”text”:”NCT04440735″,”term_id”:”NCT04440735″NCT04440735)

A phase 1 clinical trial of DSP107 alone and in combination with atezolizumab for patients with advanced solid tumors is in the recruitment phase (“type”:”clinical-trial”,”attrs”:”text”:”NCT04440735″,”term_id”:”NCT04440735″NCT04440735).… Read More »A phase 1 clinical trial of DSP107 alone and in combination with atezolizumab for patients with advanced solid tumors is in the recruitment phase (“type”:”clinical-trial”,”attrs”:”text”:”NCT04440735″,”term_id”:”NCT04440735″NCT04440735)

Speciifcally, in 2012, the use of purified polyclonal antibodies from the sera of vaccinated NHPs against the EBOV GP (treatment initiated 2 days post-challenge with EBOV) resulted in 100% survival from EBOV disease [2]

Speciifcally, in 2012, the use of purified polyclonal antibodies from the sera of vaccinated NHPs against the EBOV GP (treatment initiated 2 days post-challenge with… Read More »Speciifcally, in 2012, the use of purified polyclonal antibodies from the sera of vaccinated NHPs against the EBOV GP (treatment initiated 2 days post-challenge with EBOV) resulted in 100% survival from EBOV disease [2]